PMID- 15544697 OWN - NLM STAT- MEDLINE DCOM- 20050216 LR - 20061115 IS - 1464-2662 (Print) IS - 1464-2662 (Linking) VI - 5 IP - 6 DP - 2004 Nov TI - Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. PG - 437-47 AB - OBJECTIVES: To describe changes in the proportions of patients admitted to hospital and the duration of admission during the month of March between 1995 and 2003 and to describe the factors related to admission for 9802 patients from EuroSIDA, a pan-European, observational cohort study. METHODS: Generalized estimating equations were used to determine changes over time in the proportion of patients admitted and the median duration of admission. Logistic regression was used to determine factors related to admission in March 1995, March 1998 and March 2001. RESULTS: The proportion of patients admitted during March declined from 7.4% in 1995 to 2.6% in 2003. After adjustment, the estimated reduction in the proportion of patients admitted was 5.5% per year [95% confidence interval (CI) 2.5-8.5%; P=0.0004], a 26% reduction. The median duration of hospital admission declined by 58% from 12 days in 1995 [interquartile range (IQR) 5-19 days] to 5 days in 2003 (IQR 3-12 days), a significant decline of 0.7 days per year after adjustment (95% CI 0.5-0.9 days; P=0.031). Patients with a lower CD4 lymphocyte count, and with an AIDS diagnosis made within the 3 months prior to March, all had increased odds of admission during March 1995, 1998 or 2001. In March 2001, patients whose treatment regimen was changed as a consequence of toxicities had increased odds of admission [odds ratio (OR) 2.34; 95% CI 1.26-4.37; P=0.0074]. In addition, patients who were hepatitis C virus-positive during March 2001 (OR 1.66; 95% CI 1.02-2.68; P=0.041) had increased odds of admission. CONCLUSIONS: There has been a considerable decline in both the proportion of patients admitted to hospital and the median duration of the stay. Patients with hepatitis C had increased odds of admission, but there was little evidence of an increase in admissions among patients taking highly active antiretroviral therapy (HAART) associated with serious adverse events, although longer follow up is required. FAU - Mocroft, A AU - Mocroft A AD - Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, UK. a.mocroft@pcps.ucl.ac.uk FAU - Monforte, A d'Arminio AU - Monforte Ad FAU - Kirk, O AU - Kirk O FAU - Johnson, M A AU - Johnson MA FAU - Friis-Moller, N AU - Friis-Moller N FAU - Banhegyi, D AU - Banhegyi D FAU - Blaxhult, A AU - Blaxhult A FAU - Mulcahy, F AU - Mulcahy F FAU - Gatell, J M AU - Gatell JM FAU - Lundgren, J D AU - Lundgren JD CN - EuroSIDA study group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't PL - England TA - HIV Med JT - HIV medicine JID - 100897392 SB - IM MH - Antiretroviral Therapy, Highly Active/methods MH - CD4 Lymphocyte Count/statistics & numerical data MH - Europe/epidemiology MH - Female MH - HIV Infections/complications/drug therapy/*epidemiology MH - Hospitalization/statistics & numerical data/*trends MH - Humans MH - Incidence MH - Length of Stay/statistics & numerical data/trends MH - Longitudinal Studies MH - Male MH - Odds Ratio MH - Regression Analysis MH - Risk Factors MH - Viral Load/statistics & numerical data EDAT- 2004/11/17 09:00 MHDA- 2005/02/17 09:00 CRDT- 2004/11/17 09:00 PHST- 2004/11/17 09:00 [pubmed] PHST- 2005/02/17 09:00 [medline] PHST- 2004/11/17 09:00 [entrez] AID - HIV250 [pii] AID - 10.1111/j.1468-1293.2004.00250.x [doi] PST - ppublish SO - HIV Med. 2004 Nov;5(6):437-47. doi: 10.1111/j.1468-1293.2004.00250.x.